The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0314735 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Daniela Russo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Microenvironment Molecular Targets, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", Naples, Italy. Hauptthemen laut MEDLINE: Receptors, CXCR4, Epithelial-Mesenchymal Transition, Ovarian Neoplasms, Cell Movement. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Italiana per la Ricerca sul Cancro, Ministero della Salute, Nan4tum.
Abstract (Originalsprache)
The axis CXCL12-CXCR4 is highly expressed in ovarian cancer where contributes to disease progression. Aim of the work was to evaluate the effect of the newly developed CXCR4 antagonist R54 on human ovarian cancer cells aggressiveness. CXCL12-CXCR4 axis was evaluated in human ovarian cancer cells through proliferation, migration and signaling CXCL12-dependents. Epithelial to mesenchymal transition (EMT) was analyzed through E-CADHERIN , N-CADHERIN , VIMENTIN , SNAIL1 and ΒETA-CATENIN by qRT-PCR, immunofluorescence and immunoblotting. R54 inhibited ovarian cancer cells proliferation and migration CXCL12-induced. Moreover, R54 inhibited CXCL12 dependent pERK1/2 and pAKT and reversed the CXCL12 induced EMT in ovarian cancer cells. Targeting CXCR4 with the new antagonist R54 consistently reverted the mesenchymal transition in human ovarian cancer cells reducing migratory and chemoresistance features.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Microenvironment Molecular Targets, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", Naples, Italy.
- Uro-Gynecologic Oncology Unit, Istituto Nazionale Tumori IRCCS-Fondazione "G. Pascale", Naples, Italy.
- Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", Caserta, Italy.
ORCID-Profile: Salvatore Di Maro
Förderung
- Fondazione Italiana per la Ricerca sul Cancro
- Ministero della Salute
- Nan4tum
Zitieren
APA
Russo, D., Spina, A., Portella, L., Bello, A. M., Galdiero, F., Trotta, A. M., Ieranò, C., Rea, G., Cecere, S. C., Coppola, E., Di Maro, S., Pignata, S., Califano, D., & Scala, S. (2024). The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells. PLOS ONE. https://doi.org/10.1371/journal.pone.0314735
Vancouver
Russo D, Spina A, Portella L, Bello AM, Galdiero F, Trotta AM, et al. The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells. PLOS ONE. 2024. doi:10.1371/journal.pone.0314735
BibTeX
@article{Russo2024,
author = {Russo, Daniela and Spina, Anna and Portella, Luigi and Bello, Anna Maria and Galdiero, Francesca and Trotta, Anna Maria and Ieranò, Caterina and Rea, Giuseppina and Cecere, Sabrina Chiara and Coppola, Elisabetta and Di Maro, Salvatore and Pignata, Sandro and Califano, Daniela and Scala, Stefania},
title = {The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0314735}
}
EUVIMED